Roche announced interim results from the Phase III IMpower010 study, showing for the first time that treatment with Tecentriq (atezolizumab) following surgery and chemotherapy reduced the risk of disease recurrence or death (disease-free survival; DFS) by 34% (hazard ratio [HR]=0.66, 95% CI: 0.50–0.88) in people with Stage II-IIIA non-small cell lung cancer (NSCLC), whose tumours express PD-L1≥1%, compared with best supportive care (BSC). In this population, median DFS was not yet reached for Tecentriq compared with 35.3 months for BSC.
- Read more about Roche Tecentriq helps certain people with early lung cancer live
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/roche-tecentriq-helps-certain-people-with-early-lung-cancer-live
No comments:
Post a Comment